Download PDF
Thromb Haemost 2016; 116(01): 201-203
DOI: 10.1160/TH16-02-0116
Letters to the Editor
Schattauer GmbH

Inhibitor incidence in previously untreated patients with severe haemophilia B: a systematic literature review

Massimo Franchini
1   Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy
,
Cristina Santoro
2   Hematology, Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Rome, Italy
,
Antonio Coppola
3   Regional Reference Center for Coagulation Disorders, Federico II University Hospital, Naples, Italy
› Author Affiliations
Further Information

Publication History

Received: 12 February 2016

Accepted after minor revision: 27 March 2016

Publication Date:
27 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-391.
    CrossrefPubMedGoogle Scholar
  • 2 Collins PW, Chalmers E, Hart DP. et al. UK Haemophilia Centre Doctors. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia. 4th edition UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160: 153-170.
    PubMedGoogle Scholar
  • 3 Morfini M, Haya S, Tagariello G. et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-612.
    CrossrefPubMedGoogle Scholar
  • 4 DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138: 305-315.
    CrossrefPubMedGoogle Scholar
  • 5 Gringeri A, Mantovani LG, Scalone L. et al. for the COCIS Study Group. Cost of care and quality of life for patients with haemophilia complicated by inhibitors: the COCIS Study. Blood 2003; 102: 2358-2363.
    CrossrefPubMedGoogle Scholar
  • 6 Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in haemophilia patients with inhibitors. Semin Thromb Haemost 2013; 39: 772-778.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in haemophilia. Blood 2014; 124: 3365-3372.
    CrossrefPubMedGoogle Scholar
  • 8 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 09: 418-435.
    CrossrefPubMedGoogle Scholar
  • 10 Brooker M. World Federation of Haemophilia. Registry of clotting factor concentrates. Ninth Edition, 2012. Facts and Figures. 2012 06. 1-19 Available at http://www.wfh.org Accessed on February 9, 2016.
    PubMedGoogle Scholar
  • 9 Lee CA, Lillicrap D, Astermark J. Inhibitor development in haemophiliacs: the roles of genetic versus environmental factors. Semin Thromb Haemost 2006; 32 (Suppl. 02) 10-14.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Shapiro AD, Ragni MV, Lusher JM. et al. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with haemophilia B. Thromb Haemost 1996; 75: 30-35.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Parquet A, Laurian Y, Rothschild C. et al. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate. Thromb Haemost 1999; 82: 1247-1249.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Knobe KE, Sjörin E, Tengborn LI. et al. Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey. Acta Paediatr 2002; 91: 910-914.
    CrossrefPubMedGoogle Scholar
  • 14 Shapiro AD, Di Paola J, Cohen A. et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe haemophilia B. Blood 2005; 105: 518-525.
    CrossrefPubMedGoogle Scholar
  • 15 Kreuz W, Auerswald G, Budde U. et al. and the GTH-PUP-Study Group. In: Scharrer I, Schramm W. eds. Inhibitor development in previously untreated patients (PUPs) with haemophilia A and B. A prospective multicentre study of the German, Swiss and Austrian Society of Thrombosis and Haemostasis Research (GTH). 35th. Haemophilia Symposium, Hamburg. 2004. Heidelberg: Springer Verlag; 2005: 34-37.
    Google Scholar
  • 16 Monahan PE, Liesner R, Sullivan ST. et al. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia 2010; 16: 460-468.
    PubMedGoogle Scholar
  • 17 Fischer K, Lassila R, Peyvandi F. et al. on behalf of the EUHASS participants. Inhibitor development in haemophilia according to concentrate. Fouryear results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost 2015; 113: 968-975.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Ljung R, Petrini P, Tengborn L. et al. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol 2001; 113: 81-86.
    CrossrefPubMedGoogle Scholar
  • 19 Franchini M, Lippi G, Montagnana M. et al. Anaphylaxis in patients with congenital bleeding disorders and inhibitors. Blood Coagul Fibrinolysis 2009; 20: 225-229.
    CrossrefPubMedGoogle Scholar
  • 20 Chitlur M, Warrier I, Rajpurkar M. et al. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15: 1027-1031.
    CrossrefPubMedGoogle Scholar
  • 21 Recht M, Pollmann H, Tagliaferri A. et al. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia 2011; 17: 494-499.
    CrossrefPubMedGoogle Scholar
  • 22 Björkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia 2011; 17: 179-184.
    CrossrefPubMedGoogle Scholar
  • 23 Rocino A, Coppola A, Franchini M. et al. Principles of treatment and update of recommendations for management of haemophilia and congenital bleeding disorders in Italy. Blood Transfusion 2014; 12: 575-598.
    PubMedGoogle Scholar
  • 24 Berntorp E, Gretenkort-Andersson N. Prophylaxis for haemophilia in the era of long-acting FVIII/ FIX products. Semin Thromb Haemost. 2016 42. in press.
    PubMedGoogle Scholar